title: Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
abstract: Tumor cells are often deficient in DNA damage response (DDR) pathways, and anticancer therapies are commonly based on genotoxic treatments using radiation and/or drugs that damage DNA directly or interfere with DNA metabolism, leading to the formation of DNA double-strand breaks (DSB), and ultimately to cell death. Because DSBs induce the phosphorylation of histone H2AX (γH2AX) in the chromatin flanking the break site, an antibody directed against γH2AX can be employed to measure DNA damage levels before and after patient treatment. Poly(ADP-ribose) polymerases (PARP1 and PARP2) are also activated by DNA damage, and PARP inhibitors show promising activity in cancers with defective homologous recombination (HR) pathways for DSB repair. Ongoing clinical trials are testing combinations of PARP inhibitors with DNA damaging agents. Poly(ADP-ribosylation), abbreviated as PAR, can be measured in clinical samples and used to determine the efficiency of PARP inhibitors. This review summarizes the roles of γH2AX and PAR in the DDR, and their use as biomarkers to monitor drug response and guide clinical trials, especially phase 0 clinical trials. We also discuss the choices of relevant samples for γH2AX and PAR analyses.
authors.affiliation: Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
authors.forename: Christophe E
authors.initials: CE
authors.lastname: Redon
authors.forename: Asako J
authors.initials: AJ
authors.lastname: Nakamura
authors.forename: Yong-Wei
authors.initials: YW
authors.lastname: Zhang
authors.forename: Jiuping Jay
authors.initials: JJ
authors.lastname: Ji
authors.forename: William M
authors.initials: WM
authors.lastname: Bonner
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kinders
authors.forename: Ralph E
authors.initials: RE
authors.lastname: Parchment
authors.forename: James H
authors.initials: JH
authors.lastname: Doroshow
authors.forename: Yves
authors.initials: Y
authors.lastname: Pommier
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D054316:Biomarkers, Pharmacological / Q000032:analysis / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D004249:DNA Damage / Q000187:drug effects / Q000235:genetics; D006657:Histones / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D011064:Poly Adenosine Diphosphate Ribose / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism / Q000502:physiology; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D054316:Biomarkers, Pharmacological; D014408:Biomarkers, Tumor; C468783:H2AX protein, human; D006657:Histones; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011064:Poly Adenosine Diphosphate Ribose; D011065:Poly(ADP-ribose) Polymerases
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2705-11
references.pmid: 19364967
references.citation: Appl Immunohistochem Mol Morphol. 2008 Jul;16(4):349-56
references.pmid: 18528282
references.citation: DNA Repair (Amst). 2006 May 10;5(5):575-90
references.pmid: 16567133
references.citation: Invest Radiol. 2010 Apr;45(4):182-7
references.pmid: 20177387
references.citation: Biochem J. 1999 Sep 1;342 ( Pt 2):249-68
references.pmid: 10455009
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4527-31
references.pmid: 20823148
references.citation: Nat Rev Cancer. 2010 Apr;10(4):293-301
references.pmid: 20200537
references.citation: Ann Ist Super Sanita. 2009;45(3):265-71
references.pmid: 19861731
references.citation: DNA Repair (Amst). 2003 Sep 18;2(9):955-69
references.pmid: 12967653
references.citation: Health Phys. 2010 Feb;98(2):209-17
references.pmid: 20065685
references.citation: Nat Rev Cancer. 2006 Oct;6(10):789-802
references.pmid: 16990856
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6877-85
references.pmid: 18980982
references.citation: Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28
references.pmid: 16829982
references.citation: Nat Rev Cancer. 2008 Dec;8(12):957-67
references.pmid: 19005492
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):2140-7
references.pmid: 19276288
references.citation: Cancer Res. 2007 Oct 15;67(20):9971-9
references.pmid: 17942930
references.citation: Cell Cycle. 2005 Aug;4(8):1011-4
references.pmid: 16082209
references.citation: Cancer Res. 2004 Aug 1;64(15):5363-9
references.pmid: 15289343
references.citation: Cytometry A. 2008 Jun;73(6):508-16
references.pmid: 18431795
references.citation: Cell Cycle. 2009 Jun 15;8(12):1853-9
references.pmid: 19448405
references.citation: Cancer Res. 2008 Jan 1;68(1):257-65
references.pmid: 18172318
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4517-26
references.pmid: 20823142
references.citation: Cell Cycle. 2006 Dec;5(24):2909-13
references.pmid: 17172873
references.citation: Br J Dermatol. 2004 May;150(5):860-8
references.pmid: 15149497
references.citation: Mol Cell. 2004 Dec 22;16(6):979-90
references.pmid: 15610740
references.citation: Radiother Oncol. 2004 Sep;72(3):311-7
references.pmid: 15450730
references.citation: Nucleic Acids Res. 2009 Jun;37(11):3723-38
references.pmid: 19372272
references.citation: Radiat Oncol. 2009 Aug 24;4:31
references.pmid: 19703306
references.citation: Int J Radiat Biol. 2007 Oct;83(10):639-52
references.pmid: 17729159
references.citation: EMBO Rep. 2008 Oct;9(10):1019-26
references.pmid: 18758438
references.citation: Clin Cancer Res. 2010 Feb 1;16(3):1073-84
references.pmid: 20103672
references.citation: Nat Rev Drug Discov. 2003 Jul;2(7):566-80
references.pmid: 12838269
references.citation: Nature. 2005 Apr 14;434(7035):917-21
references.pmid: 15829967
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1239-48
references.pmid: 17406032
references.citation: Mutat Res. 2010 Jan 5;683(1-2):84-90
references.pmid: 19887075
references.citation: N Engl J Med. 2009 Jul 9;361(2):123-34
references.pmid: 19553641
references.citation: Cancer Res. 2007 Mar 15;67(6):2685-92
references.pmid: 17363589
references.citation: Circulation. 2009 Nov 10;120(19):1903-9
references.pmid: 19858412
references.citation: Curr Opin Genet Dev. 2002 Apr;12(2):162-9
references.pmid: 11893489
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4543-52
references.pmid: 20823147
references.citation: Biochem Biophys Res Commun. 1963 Apr 2;11:39-43
references.pmid: 14019961
references.citation: Nature. 2005 Apr 14;434(7035):864-70
references.pmid: 15829956
references.citation: J Biol Chem. 2003 May 30;278(22):20303-12
references.pmid: 12660252
references.citation: Mol Cancer Ther. 2007 Jun;6(6):1718-27
references.pmid: 17575103
references.citation: DNA Repair (Amst). 2006 Aug 13;5(8):935-46
references.pmid: 16814620
references.citation: Mol Cell. 2005 Dec 9;20(5):801-9
references.pmid: 16310392
references.citation: Cancer Biol Ther. 2010 Feb;9(3):246-52
references.pmid: 20023412
references.citation: J Clin Pathol. 2005 Oct;58(10):1009-15
references.pmid: 16189143
references.citation: Curr Opin Genet Dev. 2010 Feb;20(1):96-9
references.pmid: 20071161
references.citation: Science. 2002 May 3;296(5569):922-7
references.pmid: 11934988
references.citation: Cell Cycle. 2004 Feb;3(2):149-53
references.pmid: 14712078
references.citation: Cell. 2006 Jun 30;125(7):1225-7
references.pmid: 16814707
references.citation: Mol Biol Cell. 2008 Sep;19(9):3969-81
references.pmid: 18632984
references.citation: Nature. 2005 Apr 14;434(7035):913-7
references.pmid: 15829966
references.citation: Mutat Res. 2005 Oct 15;578(1-2):371-81
references.pmid: 16085124
references.citation: Cell Cycle. 2010 Jun 1;9(11):2092-6
references.pmid: 20495376
references.citation: Cancer Res. 2004 Oct 1;64(19):7144-9
references.pmid: 15466212
references.citation: Blood. 2009 Sep 24;114(13):2764-73
references.pmid: 19546476
references.citation: Blood. 2007 Sep 15;110(6):1762-9
references.pmid: 17562873
references.citation: Cancer Res. 2006 May 15;66(10):5354-62
references.pmid: 16707462
references.citation: J Biol Chem. 2004 Dec 31;279(53):55117-26
references.pmid: 15498778
references.citation: Adv Space Res. 2009;43(8):1171-1178
references.pmid: 20046946
references.citation: Cancer Res. 2005 Jun 15;65(12):5337-43
references.pmid: 15958581
references.citation: Mol Cell Biol. 2009 Jan;29(1):68-82
references.pmid: 18955500
references.citation: Genes Dev. 2005 Sep 1;19(17):1951-67
references.pmid: 16140981
references.citation: Nucleic Acids Res. 2003 Oct 1;31(19):5526-33
references.pmid: 14500814
references.citation: Radiother Oncol. 2009 Sep;92(3):310-5
references.pmid: 19604590
references.citation: Clin Cancer Res. 2010 Sep 15;16(18):4553-60
references.pmid: 20823145
references.citation: Oncogene. 2006 May 11;25(20):2839-49
references.pmid: 16407843
references.citation: Mol Cell. 2004 Dec 22;16(6):1017-25
references.pmid: 15610743
references.citation: Cancer Res. 2007 Nov 1;67(21):10397-405
references.pmid: 17974983
references.citation: Cancer Biol Ther. 2009 Nov;8(21):2004-9
references.pmid: 19823047
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2757-66
references.pmid: 17121922
references.citation: Anal Biochem. 2008 Oct 15;381(2):240-7
references.pmid: 18674509
references.citation: Cancer Res. 2010 May 15;70(10):4112-22
references.pmid: 20460517
references.citation: Nat Rev Cancer. 2007 Feb;7(2):131-9
references.pmid: 17251919
references.citation: J Biol Chem. 2008 Mar 7;283(10):6572-83
references.pmid: 18162465
references.citation: Invest Radiol. 2009 Aug;44(8):440-6
references.pmid: 19448553
references.citation: Mol Cell. 2006 Jul 7;23(1):121-32
references.pmid: 16818236
references.citation: Blood. 2009 May 14;113(20):4841-52
references.pmid: 19109557
references.citation: Bioorg Med Chem. 2006 Mar 1;14(5):1378-90
references.pmid: 16288880
references.citation: Clin Cancer Res. 2010 Apr 1;16(7):2076-84
references.pmid: 20233881
references.citation: Radiat Res. 2009 Jun;171(6):771-5
references.pmid: 19580484
references.citation: Mol Pharmacol. 2008 Jan;73(1):260-9
references.pmid: 17951356
references.citation: Mol Cell Biol. 1998 Jun;18(6):3563-71
references.pmid: 9584196
references.citation: Clin Cancer Res. 2007 May 15;13(10):3033-42
references.pmid: 17505006
references.citation: Drug Resist Updat. 2009 Dec;12(6):153-6
references.pmid: 19939726
references.citation: Radiology. 2007 Jan;242(1):244-51
references.pmid: 17185671
references.citation: Cytometry A. 2006 Apr;69(4):212-21
references.pmid: 16528719
references.citation: Immun Ageing. 2006 Jul 19;3:8
references.pmid: 16854233
references.citation: Mol Cell. 2004 Dec 22;16(6):991-1002
references.pmid: 15610741
references.citation: Science. 2006 Jun 23;312(5781):1798-802
references.pmid: 16794079
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900
references.pmid: 15279774
references.citation: Mol Cell Biol. 2010 Mar;30(6):1368-81
references.pmid: 20065038
references.citation: Radiother Oncol. 2009 Jul;92(1):133-7
references.pmid: 19167771
references.citation: J Biol Chem. 1998 Mar 6;273(10):5858-68
references.pmid: 9488723
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8984-9
references.pmid: 15956203
references.citation: Cancer Res. 2010 Jun 1;70(11):4470-80
references.pmid: 20460513
references.citation: Nature. 2005 Apr 14;434(7035):907-13
references.pmid: 15829965
references.citation: Gastroenterology. 2008 Aug;135(2):410-8
references.pmid: 18519043
references.citation: Radiology. 2008 Sep;248(3):852-9
references.pmid: 18710979